Merck & Co., Inc. (NYSE: MRK) – Pharmaceuticals and Vaccines

NYSE: MRK | Market Cap: ~$250 billion USD | Sector: Healthcare/Pharmaceuticals

---

Company Overview

Merck & Co., Inc. (known as MSD outside the United States and Canada) is one of the world’s leading pharmaceutical companies, best known for Keytruda, the world’s top-selling cancer drug. With a 130+ year history of scientific innovation, Merck develops medicines and vaccines for some of humanity’s most challenging diseases, including cancer, infectious diseases, diabetes, and immunology conditions.

Key Facts

• Founded: 1891 as the American subsidiary of German company Merck KGaA
• Headquarters: Rahway, New Jersey, USA
• NYSE Listing: 1946
• CEO: Robert M. Davis (since 2021)
• Employees: 68,000+ globally
• Operations: 140+ countries
• R&D sites: Major facilities in US, UK, Germany, China, Japan
• Market Position: Top 5 global pharmaceutical company by revenue
• Dividend Aristocrat candidate: 13+ consecutive years of dividend increases

Company Name Clarification

Merck vs. Merck KGaA

• Merck & Co. (NYSE: MRK): US-based pharmaceutical company (this article)
• Merck KGaA (DAX: MRK): German pharmaceutical/chemical company (separate entity)
• History: Originally the same company; US subsidiary separated during WWI
• Branding: US company uses “Merck” in US/Canada, “MSD” (Merck Sharp & Dohme) elsewhere

---

Business Overview

Revenue by Segment (FY2023)

Segment	Revenue	% of Total	Growth Rate
Oncology	$25.0B	42%	+20%
Vaccines	$14.2B	24%	+8%
Hospital & Specialty	$9.8B	16%	+5%
Immunology	$6.5B	11%
Other Pharma	$4.3B	7%	-2%

Total Revenue: $60.1 billion (2023)

---

Major Product Portfolio

1. Oncology (~42% of revenue)

Revenue: $25.0 billion (2023)

KEYTRUDA® (pembrolizumab) – The Crown Jewel

Overview

• Mechanism: PD-1 checkpoint inhibitor (cancer immunotherapy)
• Sales: $25.0 billion (2023) – World’s #1 selling drug
• Growth: +20% year-over-year
• Market share: ~50% of PD-1/PD-L1 inhibitor market
• Patent expiry: US 2028 (pediatric exclusivity extends to 2028), international varies

Approved Indications (40+ and counting)

Lung Cancer

• Non-small cell lung cancer (NSCLC): First-line, second-line, adjuvant, neoadjuvant
• Small cell lung cancer (SCLC): Combination therapy
• Sales contribution: ~$8 billion (largest indication)

Melanoma

• Advanced melanoma: First-line monotherapy and combination
• Adjuvant melanoma: Post-surgery to prevent recurrence
• Sales contribution: ~$2 billion

Head and Neck Cancer

• Squamous cell carcinoma: First-line and recurrent/metastatic
• Sales contribution: ~$1.5 billion

Renal Cell Carcinoma (Kidney Cancer)

• Combination therapy: With Eisai’s Lenvima (lenvatinib)
• Adjuvant therapy: Post-surgery
• Sales contribution: ~$2 billion

Bladder Cancer (Urothelial Carcinoma)

• Advanced disease: First-line and second-line
• Sales contribution: ~$1 billion

Breast Cancer

• Triple-negative breast cancer (TNBC): Combination with chemotherapy
• Sales contribution: ~$1.5 billion

Colorectal Cancer

• MSI-H/dMMR tumors: First-line treatment
• Sales contribution: ~$800 million

Gastric/Esophageal Cancer

• Gastroesophageal junction cancer: First-line combination
• Sales contribution: ~$1.2 billion

Other Indications

• Cervical cancer
• Endometrial cancer
• Hodgkin lymphoma
• Primary mediastinal B-cell lymphoma
• Merkel cell carcinoma
• Hepatocellular carcinoma (liver cancer)
• Cutaneous squamous cell carcinoma
• Biliary tract cancer

Tumor-Agnostic Indications

• MSI-H/dMMR solid tumors: Any cancer with specific genetic markers
• TMB-H tumors: High tumor mutational burden
• Revolutionary: First drug approved based on biomarker, not tumor location

Combination Therapies

• Keytruda + chemotherapy: Multiple cancer types
• Keytruda + Lenvima (Eisai): Kidney, endometrial cancer
• Keytruda + Padcev (Astellas/Seagen): Bladder cancer (approved 2024)
• Keytruda + targeted therapies: BRAF/MEK inhibitors, PARP inhibitors

Growth Drivers

• Label expansions: 5-10 new indications annually
• Earlier treatment lines: Moving from late-stage to first-line therapy
• Adjuvant/neoadjuvant: Post-surgery and pre-surgery settings
• Combination approvals: Synergistic effects with other drugs
• Geographic expansion: China approval (2018), emerging markets
• Biomarker testing: Increasing PD-L1, MSI-H, TMB-H testing

Peak Sales Potential

• Analyst estimates: $30-35 billion by 2027-2028
• Largest drug ever: Could surpass Humira’s $21B peak
• Patent cliff risk: 2028 US expiry, but biosimilar development challenging

Competitive Landscape

• Bristol Myers Squibb: Opdivo (nivolumab) – PD-1 inhibitor, #2 in class
• Roche: Tecentriq (atezolizumab) – PD-L1 inhibitor
• AstraZeneca: Imfinzi (durvalumab) – PD-L1 inhibitor
• Regeneron/Sanofi: Libtayo (cemiplimab) – PD-1 inhibitor
• Keytruda advantage: First-mover, broadest label, strongest clinical data

---

2. Vaccines (~24% of revenue)

Revenue: $14.2 billion (2023)

GARDASIL®/GARDASIL® 9 – HPV Vaccine

Overview

• Indication: Human papillomavirus (HPV) prevention
• Sales: $9.4 billion (2023)
• Growth: +15% year-over-year
• Market position: Only HPV vaccine in US (GSK’s Cervarix discontinued)

Disease Prevention

• Cervical cancer: 90% of cases caused by HPV
• Other cancers: Anal, vaginal, vulvar, penile, oropharyngeal (throat)
• Genital warts: HPV types 6 and 11
• Public health impact: Prevents 90% of HPV-related cancers

Product Evolution

• Gardasil (2006): 4-valent (HPV types 6, 11, 16, 18)
• Gardasil 9 (2014): 9-valent (adds types 31, 33, 45, 52, 58)
• Coverage: 90% of HPV-related cancers (vs 70% for Gardasil)

Target Population

• Age range: 9-45 years (FDA-approved)
• Optimal age: 11-12 years (before sexual activity)
• Dosing: 2-dose series (ages 9-14), 3-dose series (ages 15+)
• Gender-neutral: Recommended for boys and girls

Market Dynamics

• US market: ~60% vaccination rate (adolescents), room for growth
• China opportunity: Approved 2018, rapid uptake (1.4B population)
• Emerging markets: Expanding access through GAVI, government programs
• Adult catch-up: Ages 27-45 approval (2018) expanding market

Growth Drivers

• China expansion: Fastest-growing market
• Increased awareness: HPV-cancer link education
• School mandates: More states requiring HPV vaccination
• Adult vaccination: Catch-up programs for older populations
• Gender-neutral recommendations: Boys vaccination increasing

Peak Sales Potential: $12-15 billion by 2028

---

PNEUMOVAX® 23 – Pneumococcal Vaccine

Overview

• Indication: Pneumococcal disease prevention (23 serotypes)
• Sales: $1.5 billion (2023)
• Market: Adults 65+, immunocompromised individuals
• Competition: Pfizer’s Prevnar 20, Merck’s Capvaxive (approved 2024)

CAPVAXIVE® (V116) – Next-Generation Pneumococcal Vaccine

Overview

• Approval: FDA approved June 2024
• Technology: 21-valent conjugate vaccine
• Target: Adults 18+ at increased risk
• Advantage: Covers serotypes not in Prevnar 20 (8 unique serotypes)
• Launch: 2024, ramping up
• Peak sales potential: $2-3 billion

Competitive Positioning

• Pfizer Prevnar 20: Current market leader ($6.3B sales, 2023)
• Merck strategy: Capvaxive targets serotypes causing invasive disease in adults
• Clinical data: Non-inferior to Prevnar 20, superior for certain serotypes

---

VAXNEUVANCE® (V114) – Pneumococcal Vaccine

Overview

• Indication: Pneumococcal disease prevention (15 serotypes)
• Sales: $800 million (2023)
• Target: Pediatric and adult populations
• Competition: Pfizer’s Prevnar family dominates pediatric market

---

ProQuad®, M-M-R® II, VARIVAX® – Pediatric Vaccines

ProQuad® (MMRV)

• Indication: Measles, mumps, rubella, varicella (chickenpox)
• Sales: $1.2 billion (2023)
• Market: Pediatric combination vaccine

M-M-R® II

• Indication: Measles, mumps, rubella
• Sales: $800 million (2023)
• Market: Standard childhood vaccine

VARIVAX®

• Indication: Varicella (chickenpox)
• Sales: $600 million (2023)

---

ROTATEQ® – Rotavirus Vaccine

Overview

• Indication: Rotavirus gastroenteritis prevention (infants)
• Sales: $900 million (2023)
• Competition: GSK’s Rotarix
• Market: Routine infant immunization

---

3. Hospital & Specialty (~16% of revenue)

Revenue: $9.8 billion (2023)

BRIDION® (sugammadex)

Overview

• Indication: Reversal of neuromuscular blockade (anesthesia reversal)
• Sales: $1.8 billion (2023)
• Market: Operating rooms, post-surgical recovery
• Advantage: Faster, more complete reversal than neostigmine
• Growth: 10%+ annually

Antimicrobials

INVANZ® (ertapenem)

• Indication: Serious bacterial infections
• Sales: $600 million (2023)
• Market: Hospital-acquired infections

ZERBAXA® (ceftolozane/tazobactam)

• Indication: Complicated urinary tract infections, pneumonia
• Sales: $400 million (2023)
• Market: Multidrug-resistant bacteria

RECARBRIO® (imipenem/cilastatin/relebactam)

• Indication: Complicated urinary tract infections, pneumonia
• Sales: $300 million (2023)
• Market: Carbapenem-resistant bacteria

Antifungals

NOXAFIL® (posaconazole)

• Indication: Invasive fungal infections (aspergillosis, candidiasis)
• Sales: $500 million (2023)
• Market: Immunocompromised patients (cancer, transplant)

Antivirals

LAGEVRIO® (molnupiravir)

• Indication: COVID-19 treatment (oral antiviral)
• Sales: $3.2 billion (2023, declining from $5.7B in 2022)
• Partnership: Co-developed with Ridgeback Biotherapeutics
• Market: Government contracts, high-risk patients
• Future: Endemic COVID market, $500M-1B annual revenue expected

PREVYMIS® (letermovir)

• Indication: CMV (cytomegalovirus) prevention in transplant patients
• Sales: $600 million (2023)
• Growth: 15%+ annually

---

4. Immunology (~11% of revenue)

Revenue: $6.5 billion (2023)

SIMPONI® (golimumab)

Overview

• Mechanism: TNF-alpha inhibitor
• Indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis
• Sales: $2.5 billion (2023)
• Partnership: Co-marketed with Johnson & Johnson (Janssen)
• Formulations: Subcutaneous injection, IV infusion (Simponi Aria)

REMICADE® (infliximab)

Overview

• Mechanism: TNF-alpha inhibitor (IV infusion)
• Indications: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis
• Sales: $4.0 billion (2023, Merck share)
• Partnership: Co-marketed with Johnson & Johnson
• Biosimilar competition: Multiple biosimilars eroding market share
• Trend: Declining revenue due to biosimilars

---

5. Other Pharmaceuticals (~7% of revenue)

Revenue: $4.3 billion (2023)

JANUVIA®/JANUMET® (sitagliptin)

Overview

• Mechanism: DPP-4 inhibitor (oral diabetes drug)
• Indication: Type 2 diabetes
• Sales: $3.3 billion (2023)
• Formulations: Januvia (monotherapy), Janumet (+ metformin)
• Patent expiry: US 2026 (generics expected 2027)
• Challenge: GLP-1 agonists (Ozempic, Mounjaro) taking market share
• Trend: Declining revenue

ZETIA® (ezetimibe)

Overview

• Mechanism: Cholesterol absorption inhibitor
• Indication: High cholesterol
• Sales: $1.0 billion (2023)
• Generic competition: Generic ezetimibe available, but branded still prescribed

---

Research & Development Pipeline

R&D Investment

• Annual R&D spend: $13.6 billion (2023) – 23% of revenue
• Pipeline: 100+ programs in clinical development
• Focus areas: Oncology (50% of pipeline), vaccines, immunology, infectious diseases
• Strategy: Internal R&D + strategic partnerships + acquisitions

Late-Stage Pipeline (Phase III)

Oncology

Keytruda Expansion Programs

• 50+ ongoing trials: New indications, combinations, earlier treatment lines
• Adjuvant settings: Post-surgery prevention in multiple cancers
• Neoadjuvant settings: Pre-surgery tumor shrinkage
• Combination trials: With chemotherapy, targeted therapies, other immunotherapies

MK-7339 (vibostolimab + pembrolizumab)

• Mechanism: TIGIT inhibitor + PD-1 inhibitor combination
• Indications: Non-small cell lung cancer, other solid tumors
• Status: Phase III trials
• Potential: Enhancing Keytruda efficacy

Lenvima (lenvatinib) Combinations

• Partnership: Eisai (Merck has co-promotion rights)
• Mechanism: Multi-kinase inhibitor + Keytruda
• Indications: Kidney cancer, endometrial cancer, liver cancer
• Sales: $1.5 billion (Merck share, 2023)

Welireg® (belzutifan)

• Mechanism: HIF-2α inhibitor
• Approved indication: Von Hippel-Lindau (VHL) disease-associated tumors
• Pipeline: Phase III trials in renal cell carcinoma
• Potential: $2-3 billion peak sales

---

Vaccines

V116 (Capvaxive) – Pneumococcal Vaccine

• Status: Approved June 2024, launching
• Peak sales: $2-3 billion

V114 (Vaxneuvance) Expansion

• Pediatric trials: Expanding to younger age groups
• Combination vaccines: With other pediatric vaccines

RSV Vaccine (V116)

• Indication: Respiratory syncytial virus prevention
• Status: Phase III trials
• Competition: GSK, Pfizer already approved
• Market: Older adults, infants

Ebola/Marburg Vaccine (V920/V296)

• Status: Approved in Europe, US (emergency use)
• Market: Outbreak response, healthcare workers

---

Infectious Diseases

Islatravir + Doravirine (HIV)

• Mechanism: NRTTI + NNRTI combination
• Status: Phase III trials
• Potential: Long-acting HIV treatment

Clesrovimab (RSV)

• Mechanism: Monoclonal antibody for RSV prevention (infants)
• Status: Phase III trials
• Competition: Sanofi/AstraZeneca’s Beyfortus (approved)

---

Cardiovascular

MK-0616 (Oral PCSK9 Inhibitor)

• Mechanism: Oral cholesterol-lowering drug (vs injectable PCSK9 inhibitors)
• Status: Phase III trials
• Potential: $5+ billion peak sales (if successful)
• Advantage: Oral formulation vs Amgen/Sanofi injectables

---

Pulmonary Hypertension

Sotatercept

• Mechanism: Activin signaling inhibitor
• Indication: Pulmonary arterial hypertension (PAH)
• Status: Approved March 2024 as WINREVAIR®
• Sales: Launching, $2-3 billion peak potential
• Acquisition: Acceleron Pharma (2021, $11.5B)

---

Strategic Acquisitions & Partnerships

Company/Partner	Year	Price	Rationale
Prometheus Biosciences	2023	$10.8B	TL1A antibody for IBD (inflammatory bowel disease)
Acceleron Pharma	2021	$11.5B	Sotatercept (pulmonary hypertension)
Pandion Therapeutics	2021	$1.85B	Autoimmune disease pipeline
VelosBio	2020	$2.75B	ROR1-targeted antibody-drug conjugate (oncology)
ArQule	2020	$2.7B	Kinase inhibitors (oncology)
Eisai	2018	Partnership	Lenvima co-development/co-promotion
AstraZeneca	2016	Partnership	Lynparza (PARP inhibitor) co-development

---

Geographic Revenue Mix

Revenue by Region (FY2023)

Region	Revenue	% of Total	Growth Rate
United States	$33.1B	55%	+12%
Europe	$12.0B	20%	+8%
China	$6.0B	10%	+18%
Japan	$3.6B	6%	+5%
Other Markets	$5.4B	9%	+10%

China Growth Story

• Keytruda approval: 2018 (multiple indications approved)
• Gardasil 9 approval: 2018 (rapid uptake)
• Growth rate: 18%+ annually
• Opportunity: 1.4 billion population, expanding healthcare access

---

Competitive Landscape

Oncology

PD-1/PD-L1 Inhibitors

• Merck (Keytruda): $25B sales, ~50% market share, broadest label
• Bristol Myers Squibb (Opdivo): $8B sales, strong in combination therapies
• Roche (Tecentriq): $3B sales, PD-L1 inhibitor
• AstraZeneca (Imfinzi): $3B sales, strong in lung cancer
• Merck advantage: First-mover, most approvals, strongest data

Vaccines

HPV Vaccines

• Merck (Gardasil 9): Monopoly in US, dominant globally
• GSK (Cervarix): Discontinued in US, limited international presence
• Chinese manufacturers: Lower-cost alternatives in China

Pneumococcal Vaccines

• Pfizer (Prevnar 20): Market leader, $6.3B sales
• Merck (Capvaxive, Vaxneuvance): Challenger, gaining share
• GSK: Exiting pneumococcal vaccine market

Diabetes

Oral Diabetes Drugs

• Merck (Januvia): DPP-4 inhibitor, declining due to GLP-1 competition
• Eli Lilly (Mounjaro): GLP-1/GIP agonist, blockbuster
• Novo Nordisk (Ozempic): GLP-1 agonist, dominant
• AstraZeneca (Farxiga): SGLT2 inhibitor, growing

---

Financial Performance

Revenue Trends

Year	Revenue	Growth	Notes
2019	$46.8B	+11%	Pre-COVID baseline
2020	$48.0B	+3%	COVID impact on procedures
2021	$48.7B	+1%	Lagevrio launch (COVID drug)
2022	$59.3B	+22%	Lagevrio peak, Keytruda growth
2023	$60.1B	+1%	Lagevrio decline, base business +7%
2024E	$63-65B	+5-8%	Keytruda, Gardasil driving growth

Profitability Metrics (FY2023)

• Gross margin: 77.8%
• Operating margin: 30.5%
• Net profit margin: 23.8%
• Adjusted net profit margin: 28.5%
• Return on equity (ROE): 32.1%
• EBITDA: $22.4 billion
• EBITDA margin: 37.3%

Earnings Per Share

• Reported EPS: $5.72 (2023)
• Adjusted EPS: $7.54 (2023)
• 2024 guidance: $8.53-$8.65 adjusted EPS
• Long-term growth: 10%+ adjusted EPS growth target

Dividend History

• Annual dividend: $3.08 per share (2024)
• Dividend yield: 2.6-2.8%
• Payout ratio: ~40% of adjusted earnings
• Consecutive increases: 13+ years
• Dividend growth: 7-8% annually (10-year average)
• Quarterly payments: January, April, July, October

Balance Sheet (FY2023)

• Total assets: $118.5 billion
• Cash and investments: $14.4 billion
• Total debt: $32.3 billion
• Net debt: $17.9 billion
• Debt/EBITDA: 0.8x (low leverage)
• Credit rating: AA (S&P), Aa2 (Moody’s) – strong investment grade

Cash Flow (FY2023)

• Operating cash flow: $18.5 billion
• Free cash flow: $16.2 billion
• Capex: $2.3 billion (~4% of revenue)
• Cash conversion: 113% of net income

Capital Allocation (FY2023)

• Dividends: $7.8 billion
• Share buybacks: $3.0 billion
• Total shareholder returns: $10.8 billion (67% of free cash flow)
• M&A: $10.8 billion (Prometheus Biosciences)
• R&D: $13.6 billion (23% of revenue)

---

Investment Thesis

Bull Case 🐂

Keytruda Dominance

• $25B sales (2023): World’s #1 selling drug
• 20%+ growth: Sustained double-digit growth
• Label expansion: 5-10 new indications annually
• Earlier treatment lines: Moving from late-stage to first-line, adjuvant, neoadjuvant
• Combination approvals: Synergistic effects with chemotherapy, targeted therapies
• Peak sales potential: $30-35 billion by 2027-2028
• Patent life: US exclusivity through 2028, biosimilar development challenging

Gardasil Growth Engine

• $9.4B sales (2023): Growing 15%+ annually
• China opportunity: Fastest-growing market, 1.4B population
• Low penetration: US ~60% vaccination rate, room for growth
• Adult catch-up: Ages 27-45 approval expanding market
• Emerging markets: Expanding access through GAVI, government programs
• Peak sales potential: $12-15 billion

Diversified Revenue

• Oncology (42%): Keytruda + pipeline
• Vaccines (24%): Gardasil, pneumococcal, pediatric
• Hospital (16%): Bridion, antimicrobials, antivirals
• Immunology (11%): Simponi, Remicade
• Geographic diversification: 55% US, 45% international

Strong Pipeline

• Winrevair (sotatercept): Approved 2024, $2-3B peak potential (pulmonary hypertension)
• Capvaxive (V116): Approved 2024, $2-3B peak potential (pneumococcal vaccine)
• MK-0616: Oral PCSK9 inhibitor, $5B+ potential (cholesterol)
• Prometheus TL1A antibody: $10.8B acquisition, IBD blockbuster potential
• Keytruda combinations: 50+ ongoing trials

Financial Strength

• High margins: 77.8% gross margin, 30.5% operating margin
• Strong cash flow: $16.2B free cash flow
• Low leverage: 0.8x debt/EBITDA
• Shareholder returns: $10.8B dividends + buybacks (2023)
• M&A capacity: Balance sheet supports bolt-on acquisitions

Defensive Characteristics

• Essential medicines: Cancer drugs, vaccines non-discretionary
• Recession-resistant: Healthcare spending stable
• Pricing power: Innovative therapies command premium prices
• Dividend growth: 13+ years of consecutive increases

Bear Case 🐻

Risks and Challenges

Keytruda Patent Cliff (2028)

• US patent expiry: 2028 (pediatric exclusivity)
• Revenue at risk: $25B+ annual sales
• Biosimilar threat: Multiple companies developing biosimilars
• Difficult to replace: Few drugs generate $25B+ annually
• Margin impact: Keytruda has high margins
• Investor concern: 42% of revenue from single drug

Pipeline Execution Risk

• Late-stage failures: Clinical trials can fail (high risk in pharma)
• Competitive threats: Crowded oncology, vaccine markets
• Regulatory delays: FDA approvals unpredictable
• Acquisition integration: Prometheus ($10.8B) execution risk

Januvia Patent Expiry (2026)

• US patent expiry: 2026 (generics 2027)
• Revenue at risk: $3.3B annual sales
• GLP-1 competition: Ozempic, Mounjaro taking market share
• Declining revenue: Already falling before patent expiry

Remicade Biosimilar Erosion

• Biosimilar competition: Multiple biosimilars approved
• Revenue decline: Falling 10-15% annually
• Margin pressure: Lower-priced biosimilars

Lagevrio Revenue Decline

• Peak (2022): $5.7 billion
• Current (2023): $3.2 billion
• Future: $500M-1B endemic market
• Difficult to replace: $5B revenue loss

Regulatory & Pricing Pressure

• Inflation Reduction Act: Medicare drug price negotiation
• Keytruda targeted: Could be selected for 2027-2028 negotiation
• International price controls: Europe, Japan, China limiting drug prices
• Rebate pressure: PBMs demanding higher rebates

Competition Intensifying

• Oncology: Next-generation immunotherapies (bispecifics, CAR-T, ADCs)
• Vaccines: Pfizer pneumococcal vaccines competing with Capvaxive
• Diabetes: GLP-1 agonists dominating (Eli Lilly, Novo Nordisk)

Valuation

• Premium multiple: Trading at 18-20x P/E (above historical average)
• High expectations: Keytruda growth priced in
• Patent cliff risk: 2028 expiry creates uncertainty
• Limited upside: Stock near all-time highs

---

Valuation Metrics

Current Trading Multiples (indicative)

• P/E Ratio: 18-20x
• Forward P/E: 16-18x
• Price-to-Sales: 4.2-4.6x
• Price-to-Book: 6.0-7.0x
• EV/EBITDA: 13-15x
• Dividend Yield: 2.6-2.8%

Comparison to Peers

Company	P/E	Div Yield	Market Cap	Key Strengths
Merck	18x	2.8%	$250B	Keytruda dominance, Gardasil, vaccines
Pfizer	10x	6.5%	$150B	High yield, Seagen ADCs, post-COVID transition
Johnson & J	16x	3.1%	$380B	Diversification, dividend aristocrat
AbbVie	15x	3.5%	$320B	Immunology leadership, high yield
Eli Lilly	55x	0.7%	$750B	GLP-1 dominance (Mounjaro, Zepbound)
Bristol Myers	12x	4.5%	$100B	Oncology, Eliquis, high yield

Observation: Merck trades at premium to diversified pharma, reflecting Keytruda dominance and vaccine franchise strength

---

Key Catalysts to Monitor

Near-Term (2026)

• Quarterly earnings: Keytruda growth, Gardasil momentum, guidance
• Keytruda label expansions: New indication approvals
• Capvaxive uptake: Pneumococcal vaccine market share gains
• Winrevair launch: Pulmonary hypertension drug adoption
• MK-0616 Phase III data: Oral PCSK9 inhibitor trial results

Medium-Term (2027-2028)

• Keytruda patent expiry: 2028 US exclusivity loss, biosimilar impact
• Januvia patent expiry: 2026 US, generics 2027
• Pipeline approvals: Prometheus TL1A antibody, oncology programs
• Gardasil peak sales: Approaching $12-15B
• M&A activity: Bolt-on acquisitions to fill pipeline gaps

Long-Term (2029+)

• Post-Keytruda strategy: Replacing $25B+ revenue
• Next-generation immunotherapies: Bispecifics, ADCs, cell therapies
• Vaccine expansion: RSV, combination vaccines
• Emerging markets: China, India growth acceleration

---

How to Invest in Merck

Direct Stock Purchase

• NYSE: MRK – New York Stock Exchange
• Available through US and international brokers
• Dividend Reinvestment Plan (DRIP) available
• Highly liquid – easy to buy/sell

ETF Exposure

• Health Care Select Sector SPDR (XLV) – ~6% MRK weighting
• iShares U.S. Healthcare ETF (IYH) – ~5% MRK weighting
• Vanguard Health Care ETF (VHT) – ~4% MRK weighting
• SPDR S&P Dividend ETF (SDY) – Dividend growth exposure

Options Strategies

• Covered calls: Generate income on stock holdings
• Cash-secured puts: Acquire shares at lower prices
• Dividend capture: Buy before ex-dividend date

---

Analyst Consensus (Indicative)

Ratings Distribution

• Buy: 55% of analysts
• Hold: 42% of analysts
• Sell: 3% of analysts

Price Target Range

• Bull case: $135-145 USD
• Base case: $120-130 USD
• Bear case: $100-110 USD

Note: Analyst opinions vary based on Keytruda patent cliff assumptions, pipeline execution, and biosimilar impact timing

---

Tax Considerations (US Investors)

Dividends

• Qualified dividends: Taxed at long-term capital gains rates (0%, 15%, or 20%)
• Holding period: Must hold stock 60+ days around ex-dividend date
• Tax-advantaged accounts: IRA, 401(k) dividends grow tax-deferred

Capital Gains

• Long-term: Held 12+ months, taxed at 0%, 15%, or 20%
• Short-term: Held less than 12 months, taxed as ordinary income

International Investors

• Withholding tax: 30% US tax on dividends (reduced by tax treaty)
• Australian investors: 15% withholding under US-Australia tax treaty
• Foreign tax credit: Can claim credit in home country

---

ESG Considerations

Environmental

• Carbon neutrality goal: Net-zero emissions by 2050
• Renewable energy: 100% renewable electricity by 2025
• Water stewardship: Reducing water usage in manufacturing
• Sustainable packaging: Recyclable materials
• Pharmaceutical waste: Proper disposal programs

Social

• Access to medicines: Tiered pricing for developing countries
• Gardasil donations: GAVI partnership for low-income countries
• Clinical trial diversity: Increasing underrepresented populations
• Employee health: Comprehensive benefits, mental health support
• Community engagement: Merck for Mothers, Merck Foundation charitable giving

Governance

• Independent board (11 of 12 directors independent)
• Separate CEO and Chairman roles
• Executive compensation tied to long-term performance and ESG metrics
• Transparent financial reporting
• Strong regulatory compliance programs

ESG Controversies

• Drug pricing (high US prices vs international)
• Vioxx litigation (historical, settled)
• Gardasil marketing practices (scrutiny in some countries)

ESG Ratings: Generally strong scores from major rating agencies

---

Related Terms

• PD-1 checkpoint inhibitor – Cancer immunotherapy blocking PD-1 protein
• HPV (Human Papillomavirus) – Virus causing cervical and other cancers
• Biosimilar – Generic version of biologic drug
• Patent cliff – Revenue loss when drug patents expire
• Blockbuster drug – Drug with $1B+ annual sales
• Adjuvant therapy – Treatment after surgery to prevent recurrence
• Neoadjuvant therapy – Treatment before surgery to shrink tumors
• MSI-H/dMMR – Genetic biomarkers for cancer immunotherapy response
• TMB-H – Tumor mutational burden (high) biomarker
• DPP-4 inhibitor – Oral diabetes drug class (Januvia)

---

Disclaimer: This information is for educational purposes only and does not constitute financial or medical advice. Merck stock carries risks including Keytruda patent expiry (2028), pipeline execution failures, biosimilar competition, Januvia patent cliff, regulatory/pricing pressures, and competitive threats. DYOR before making investment decisions. Past performance is not indicative of future results. Consult with financial advisors regarding investment decisions and healthcare professionals regarding medical products.

---

Official Website: www.merck.com

Investor Relations: investors.merck.com

NYSE Listing: www.nyse.com (Code: MRK)

SEC Filings: www.sec.gov (Search: Merck & Co)

Related Topics: Merck, NYSE:MRK, Pharmaceutical Stocks, Keytruda, Pembrolizumab, Cancer Immunotherapy, PD-1 Inhibitor, Gardasil, HPV Vaccine, Vaccines, Oncology Drugs, Checkpoint Inhibitors, Patent Cliff, Biosimilars, Dividend Stocks, Healthcare Stocks, Drug Pricing, Capvaxive, Winrevair, Januvia, Lagevrio